Physician profile
Patrick Michael Veerkamp
NPI 1174059109
$12,000.98
in general payments reported to CMS, 2019-2025
26 companies · $2,604 in 2025
The $2,604 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $65.08 · 2021: $628 · 2022: $1,703 · 2023: $4,186 · 2024: $2,707 · 2025: $2,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,381 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,726 · Education: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,381.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,725.75 |
| Education | $389.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,488.79 | 2021-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $766.12 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $584.38 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $556.17 | 2021-2025 | Tremfya |
| Ucb, INC. | $533.61 | 2022-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $527.64 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $461.20 | 2021-2025 | Ilumya |
| Incyte Corporation | $410.84 | 2022-2025 | Opzelura |
| Strata Skin Sciences, INC. | $400.34 | 2023 | Xtrac |
| Leo Pharma INC. | $381.33 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $286.16 | 2021-2025 | Nemluvio |
| Genentech USA, INC. | $256.41 | 2019-2021 | |
| Pfizer INC. | $210.83 | 2022-2023 | |
| Amgen INC. | $193.33 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $183.14 | 2021-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $162.99 | 2022-2023 | Keytruda |
| Sanofi-Aventis U.S. LLC | $151.99 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.60 | 2022-2024 | Spevigo, Cyltezo |
| Novartis Pharmaceuticals Corporation | $104.15 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $86.03 | 2025 | Acthar |
| Kyowa Kirin, INC. | $54.77 | 2021-2024 | Poteligeo |
| Qiagen, LLC | $22.30 | 2023 | |
| Organon LLC | $21.27 | 2025 | Hadlima, Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.08 | 2021 | |
| Mayne Pharma Commercial LLC | $18.66 | 2022 | |
| Biofrontera INC. | $10.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Veerkamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.